Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC) Grant

Pfizer is launching a grant initiative to enhance care for patients with advanced ALK+ non-small cell lung cancer (NSCLC). This program aims to support independent medical education projects focusing on patient and caregiver preparation for ALK inhibitor therapy, side-effect management, and the development of resources that promote informed decision-making and accessibility. By addressing the challenges faced by this patient population, the initiative seeks to improve treatment outcomes and quality of life.

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC)
Overview
Pfizer and ALK Positive are collaborating to offer a new grant opportunity seeking proposals for independent medical education initiatives. Lung cancer remains the most commonly diagnosed cancer worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Among NSCLC subtypes, advanced ALK-positive NSCLC represents 2% to 7% of NSCLC cases and is characterized by aggressive disease progression and frequent central nervous system involvement. Targeted therapies, known as ALK tyrosine kinase inhibitors (TKIs), have transformed treatment outcomes for these patients, improving disease control with a manageable side effect profile.
Through this effort, our goals are to help individuals diagnosed with advanced ALK+ non-small cell lung cancer (NSCLC) by supporting projects that focus on:
Preparation of patients and care partners for ALK inhibitor therapy, side-effect management, including what to expect during treatment and how to engage with their healthcare team.Development of material pertaining to prompt side-effect (adverse events) recognition, including lifestyle recommendations, to preserve / support quality of life.Development of tools that emphasize patient preferences, facilitate preference-informed decisionmaking, and ensure inclusivity and accessibility for example: providing multilingual resources.